Nabla, the Paris-based startup making waves in the healthcare sector, has recently announced a successful Series B funding round, securing an impressive $24 million. The round was led by Cathay Innovation, with participation from ZEBOX Ventures, the corporate VC fund associated with CMA CGM. This significant funding injection closely follows Nabla’s strategic partnership with Permanente Medical Group, a division of the renowned U.S. healthcare giant Kaiser Permanente.
Post this funding round, Nabla has soared to a valuation of $180 million, and additional contributions from U.S. investors are on the horizon. At the heart of Nabla’s innovation is an AI copilot designed to support doctors and medical staff. Picture it as an unobtrusive assistant in the corner of the room, diligently taking notes and crafting detailed medical reports during consultations.
Founded by Alexandre Lebrun, Delphine Groll, and Martin Raison, Nabla’s CEO, Alexandre Lebrun, brings significant expertise from his tenure as the CEO of Wit.ai, an AI assistant startup acquired by Facebook. Nabla’s solution employs speech-to-text technology to transcribe both in-person and telehealth consultations. A recent live demo showcased the tool’s remarkable accuracy and efficiency in generating transcripts and comprehensive medical reports.
Named Nabla Copilot, the startup emphasizes collaboration with human professionals rather than seeking to replace them. Physicians maintain ultimate control, with the ability to edit reports before integrating them into their electronic health record (EHR) systems. Nabla envisions a gradual progression in automation levels, analogous to the stages of autonomous vehicles, incorporating clinical assurance support and clinical decision support with FDA approval.
While Nabla is headquartered in France, its primary customer base is in the U.S., particularly following its successful rollout across Permanente Medical Group. Nabla is not just a conceptual solution; it is actively utilized by thousands of doctors daily, representing a tangible and impactful contribution to the healthcare landscape.